<DOC>
	<DOCNO>NCT00694590</DOCNO>
	<brief_summary>The purpose research study determine plerixafor make CLL/SLL ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma ) cell sensitive kill rituximab , anti-cancer drug commonly use treat CLL SLL . In study , plerixafor added standard treatment rituximab . Subjects monitor see well tolerate use drug together well work treat leukemia . The primary objective determine maximum tolerate dose ( MTD ) plerixafor combine rituximab treatment previously treat patient CLL SLL .</brief_summary>
	<brief_title>Study AMD3100 ( Plerixafor ) Rituximab Patients With Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Females child bear potential must agree abstain sexual activity use medically approve contraceptive measure/regimen 3 month treatment period surgically sterile . Males must agree abstain sexual activity agree utilize medically approve contraception method treatment 3 month treatment period surgically sterile . Diagnosis CLL SLL , relapse least one prior therapy . CLL/SLL cell express CD20 document screen . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Life expectancy least 12 week . Serum creatinine ≤2.0 mg/dL . Total bilirubin ≤2.0 mg/dL . ALT ( alanine aminotransferase ) AST ( aspartate aminotransaminase ) ≤2 time upper limit normal ( ULN ) ; patient liver involvement CLL/SLL disease , limit increase ≤5 time ULN . At time enrollment , patient must &gt; 4 week since major surgery , radiotherapy , chemotherapy ( &gt; 6 week chemotherapy ) , immunotherapy , biotherapy/targeted investigational therapy recover toxicity prior treatment ≤ grade 1 . White Blood Cells ( WBC ) &gt; 250 x 10^9 cells/L . Disease refractory rituximab therapy define failure respond prior rituximabcontaining regimen . Women breastfeed . Active viral hepatitis . Active infection treatment antimicrobial antiviral therapy within 1 week enrollment exception prophylactic therapy . History prior allergic reaction plerixafor rituximab . Significant lung disease . Serious cardiac disease history sustain ventricular arrhythmia , uncontrolled serious congestive heart failure ( CHF ) , angina , acute coronary syndrome , myocardial infarction within 6 month enrollment significant medical psychosocial condition warrant exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>AMD3100</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>SLL</keyword>
</DOC>